Format

Send to

Choose Destination
Annu Rev Med. 2016;67:487-95. doi: 10.1146/annurev-med-120214-013614. Epub 2015 Nov 4.

Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.

Author information

1
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048; email: Anna.Selvaggio@cshs.org , Paul.Noble@cshs.org.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease that has long eluded therapy. Prognosis remains very poor, and currently lung transplantation offers the only hope of survival. Recently, great strides have been made in the development of pharmaceutical therapy to treat IPF. Pirfenidone, an oral antifibrotic agent, has been shown to slow progression of the disease and improve progression-free survival, offering new hope for patients suffering from IPF.

KEYWORDS:

EsbrietĀ®; idiopathic pulmonary fibrosis; interstitial lung disease; pirfenidone

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center